The market’s harsh reaction to the Q4 miss seems unreasonable
08/02/24 -"Even though Q4 profitability fell short of the street’s expectations, the 2023 results met the management’s CER guidance. The management’s 2024 outlook was healthy as well. Still, the share price ..."
Pages
72
Language
English
Published on
08/02/24
You may also be interested by these reports :
12/12/24
Lonza conducted a well-attended investor update, positioned between a standard analyst presentation and an investor or capital markets day. Key ...
12/12/24
After integrating the latest financial figures, we have further reduced the operating expense (opex) forecast for 2024. The impact is however minimal ...
09/12/24
Lonza shares (Add; Switzerland) have experienced significant growth over the past decade, peaking in 2022. The appointment of Mr Ridinger was ...
09/12/24
With some of AstraZeneca’s key executives in China being under investigation by the local authorities, the shares have experienced negative momentum ...